2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neoplasms
2
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Multiple Endocrine Neoplasia Type 1
1
Lung Cancer Metastatic
1
Hyperlipoproteinemia Type II
1
Glioma
1
Glioblastoma
1
Coronary Disease
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Atherosclerosis
1
Interventions
evolocumab
1
Vitamin E
1
Vitamin D
1
Risk Assessment
1
Progestins
1
Progesterone
1
Methods
1
Hormone Replacement Therapy
1
Estrogens
1
Estrogen Replacement Therapy
1
Estradiol
1
Electrocardiography
1
Dietary Supplements
1
Diet, Fat-Restricted
1
Calcium
1
Aspirin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Coronary Disease
×
evolocumab
×
Clear all
NCT03872401
2025-11-10
VESALIUS-CV
Amgen
Phase 3
Completed
12,301 enrolled